I point the Nov 1994 article in the Archives of Surgery. I do have the abstract, and I post the link to it.
It is clear that there were four initial groups (placebo, 0.1mg, 1mg and 2mg) and the "statistical significance" comes after the fact, meaning the data was already in, and the regrouping that showed the statistical significance was done after, not planed before the study.
It can be read clearly that they are not claiming statistical significance, but a trend(Abstract). Full article I will review when I find the time.
The second hand report I linked, was for anybody in the thread interested in a good review of the work in pgg-glucan(Betafectin). They also report another trial in trauma patients that did claim statistical significance (with even less patients). I did not comment that second study because I have not had time to check even the abstract.
The other review, please fax to 201-862-9104. If not in your area, do not worry I will certainly look for it. Thank you a lot for the reference and the fax offer.
Besides P value one needs the Power too(80%, 90%, 95% ?) and that will determine the number of patients you will need, and this is to be done first, not after the study.
I do think the company efforts in the phase III study looks very responsible and well designed. If you have the protocol for the study, I will like to see it.
My point is you are making a good guess investing your money in ABTI, but still a guess. And for that you can make tons of money if right, or loss tons of money if wrong. Any guess why the share price is just aroud $9 and not already $90, simple there are tons of people waiting outside, not inside.
Nuber of mutual funds that own ABTI is 14 (good sign, if compared to ZONA 1, or XOMA 18), as per Investor's Business Daily stocks list. |
